We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
The Automation Partnership's Advanced Projects Group Announces Successful Collaboration with Cellectricon
News

The Automation Partnership's Advanced Projects Group Announces Successful Collaboration with Cellectricon

The Automation Partnership's Advanced Projects Group Announces Successful Collaboration with Cellectricon
News

The Automation Partnership's Advanced Projects Group Announces Successful Collaboration with Cellectricon

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "The Automation Partnership's Advanced Projects Group Announces Successful Collaboration with Cellectricon"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Automation Partnership (TAP) has announced its Advanced Projects Group, has successfully collaborated with Cellectricon, the Swedish provider of screening solutions for drug discovery, to produce fully automated high throughput patch clamp equipment known as the Dynaflow®HT System.

Patch clamping is the gold standard for screening ion channels in drug discovery. Currently, few commercial instruments exist for high throughput primary and secondary screening so TAP’s Advanced Projects Group of specialist engineers, software designers and biologists have worked closely with Cellectricon to produce the Dynaflow®HT System to meet this need.

The Dynaflow®HT System, which has been developed in collaboration with AstraZeneca in Sweden is now becoming commercially available and addresses the limits of existing ion channel screening equipment by combining high levels of automated throughput with data measurement.
Advertisement